What about ezetimibe without statin? Is it an effective therapy?

The short version: ezetimibe without a statin is not what the major trials tested, so the evidence for monotherapy is thin.

Every large trial that showed a benefit from ezetimibe added it to a statin. The IMPROVE-IT trial tested ezetimibe 10 mg plus simvastatin 40 mg against simvastatin alone, not ezetimibe alone [2]. The 2024 Korean cohort compared moderate statin plus ezetimibe against high-intensity statin alone [1]. The 2025 diabetes cohort did the same [3]. None of these studies had an ezetimibe-only arm.

What the evidence does show is that ezetimibe adds about a 12 mg/dL extra LDL reduction on top of a statin [5]. A 2024 meta-analysis of 11 studies found that upfront statin plus ezetimibe reduced cardiovascular mortality by about 25% compared to statin alone (OR 0.75) [5]. But that is the combination, not monotherapy.

The only record that touches ezetimibe alone is a 2012 Japanese survey where a small number of patients were on ezetimibe monotherapy or with other non-statin agents [4]. That study measured LDL goal attainment, not cardiovascular events. It cannot answer the effectiveness question.

The mechanism of ezetimibe is blocking intestinal cholesterol absorption. It will lower LDL on its own, typically by 15-20%. But no trial in this retrieval tested whether that LDL drop, without a statin, translates into fewer heart attacks or strokes.

My call: ezetimibe monotherapy has not been shown to reduce cardiovascular events. The evidence for benefit comes entirely from combination with a statin. If someone cannot tolerate statins, ezetimibe alone is a plausible LDL-lowering agent, but its effect on real outcomes is unproven by the studies here. Confidence: low.